ArticleIndian journal of ophthalmology2026
Reper intraocular lens with artificial iris: Presentation and outcomes in patients with significant iris defects and Aphakia.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Reper device (Reper-NN LTD, Nizhny Novgorod, Russia), an acrylic iris diaphragm combined with an intraocular lens (IOL), may be adapted for patients with various iris defects and aphakia. We aim to present our experience using the Reper artificial iris-IOL device.
settingTertiary medical center.
methodsThis study includes patients who underwent implantation of the Reper artificial iris-IOL device at a single tertiary medical center between 2017 and 2023. The non-parametric signed test was used to compare preoperative and postoperative outcomes.
resultsFifteen patients with aphakia and partial aniridia were included (four females [27%], mean age: 68.3). Mean follow-up time was 7.87 ± 5.62 months (range: 1-20). Following surgery, 87% (13 patients) showed improvement in corrected distance visual acuity (CDVA), while 13% (two patients) maintained their preoperative CDVA. The mean improvement in CDVA was 0.68 ± 0.19 logMAR (P value = 0.0015 [95% confidence interval (CI): 0.28-1.08. Unpaired t-test]). Moreover, all patients (100%) expressed complete satisfaction with postoperative cosmetic outcomes.
conclusionThis study represents the largest reported series on Reper artificial iris-IOL implantation procedure and provides initial insights into its outcomes. No surgical complications were reported, and most patients experienced VA improvement and cosmetic satisfaction. These findings may assist ophthalmic surgeons in evaluating the benefits and risks of this implant. Larger, longer-term studies are needed to better establish its safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.